(3E)-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1$l^{6},2-benzothiazine-1,1,4-trione

• ChemBase编号: 436
• 分子式: C15H13N3O4S
• 平均质量: 331.34642
• 单一同位素质量: 331.06267691
• SMILES: S1(=O)(=O)N(/C(=C(/O)\Nc2ncccc2)/C(=O)c2c1cccc2)C
• Canonical SMILES: O/C(=C/1\C(=O)c2ccccc2S(=O)(=O)N1C)/Nc1ccccn1
• InChI: InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,20H,1H3,(H,16,17)/b15-13+
• InChIKey: LDJVNWFKNMYYNT-FYWRMAATSA-N

名称和登记号

名称

• IUPAC标准名: (3E)-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1$l^{6},2-benzothiazine-1,1,4-trione
• IUPAC传统名: akten
• 商标名: Apo-Piroxicam; Artroxicam; Baxo; Bruxicam; Caliment; Erazon; Feldene; Flogobene; Geldene; Improntal; Larapam; Pipoxicam; Pirkam; Piroflex; Reudene; Riacen; Roxicam; Roxiden; Sasulen; Solocalm; Zunden; piroxicam usp; Akten
• 别名: piroxicam; AK1015; Piroxicam

登记号

• CAS号: 36322-90-4
• PubChem SID: 160963899
• PubChem CID: 54676228

理论计算性质

JChem

• Acid pKa: 7.5554237
• 质子受体: 6
• 质子供体: 2
• LogD (pH = 5.5): 1.230431
• LogD (pH = 7.4): 1.0765729
• Log P: 1.3089457
• 摩尔折射率: 96.1692 cm^3
• 极化性: 32.561253 Å^3
• 极化表面积: 99.6 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 1.81
• LOG S: -3.74
• 溶解度: 6.05e-02 g/l

分子性质

理化性质

• 溶解度: 23 mg/L
• 疏水性(logP): 3

详细说明

DrugBank - DB00554

• Drug Groups: approved; investigational
• Description: A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. [PubChem]
• Indication: For treatment of osteoarthritis and rheumatoid arthritis.
• Pharmacology: Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.
• Toxicity: Symptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting.
• Affected Organisms: Humans and other mammals
• Biotransformation: Renal
• Absorption: Well absorbed following oral administration.
• Half Life: 30 to 86 hours
• Elimination: Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a piroxicam dose is excreted unchanged. However, a substantial portion of piroxicam elimination occurs by hepatic metabolism. Piroxicam is excreted into human milk.
• Distribution: * 0.14 L/kg
• External Links: Wikipedia; RxList; PDRhealth; Drugs.com